Increased prevalence of infectious diseases, outbreaks, and pandemics worldwide is expected to drive market expansion in the near future at a CAGR of 11.50% during the forecast period 2024 to 2032

Market Research Future (MRFR) has published on the “Global Vaccine Contract Manufacturing Market”.

The Vaccine Contract Manufacturing market is estimated to register a CAGR of 11.50% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global Vaccine Contract Manufacturing market— Emergent BioSolutions Inc., Catalent, Inc., Lonza Group AG, Fujifilm Diosynth Biotechnologies, Wuxi Biologics, Samsung Biologics, Boehringer Ingelheim, Novavax, Inc., BioNTech SE, CSL Limited and Others.

Vaccine Contract Manufacturing Market Highlights

The global Vaccine Contract Manufacturing market is accounted to register a CAGR of 11.50% during the forecast period and is estimated to reach USD 7.9 billion by 2032.

The Vaccine Contract Manufacturing market is expanding due to several factors. With the rising demand for vaccines globally, pharmaceutical companies are increasingly outsourcing manufacturing to specialized contract manufacturing organizations (CMOs). This allows for increased production capacity, flexibility, and access to advanced technologies. Moreover, the need for rapid vaccine development and production in response to emerging infectious diseases further drives the growth of the Vaccine Contract Manufacturing market.

Explore In-depth Details: Vaccine Contract Manufacturing Market Research Report

Segment Analysis

The global Vaccine Contract Manufacturing market has been segmented based on Vaccine Type, Workflow and Application.

On the basis of Vaccine Type, the market is segmented into Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based. The Attenuated Vaccine Type captured the largest market share in 2023 due to its effectiveness in stimulating immune responses while offering safety advantages. Attenuated vaccines, which contain weakened forms of pathogens, provide robust and long-lasting immunity with fewer doses. Their proven efficacy and widespread use contribute to their dominance in the Vaccine Contract Manufacturing market.

Based on Workflow, the global Vaccine Contract Manufacturing market has been segmented into Downstream and Upstream. The Downstream Workflow captured the largest market share in 2023 due to its critical role in vaccine production, including purification, concentration, and formulation. Efficient downstream processes ensure high product yield, purity, and quality, meeting regulatory standards. Moreover, advancements in downstream technologies enhance productivity and scalability, driving their dominance in the Vaccine Contract Manufacturing market.

Based on Application, the global Vaccine Contract Manufacturing market has been segmented into Human Use and Veterinary. The Human Use Application captured the largest market share in 2023 due to the increasing demand for vaccines to prevent and control infectious diseases in humans. Contract manufacturers specialize in producing vaccines for human use, meeting regulatory requirements and ensuring safety and efficacy, driving their dominance in the Vaccine Contract Manufacturing market.

Regional Analysis

The global Vaccine Contract Manufacturing market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The Europe Vaccine Contract Manufacturing market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Vaccine Contract Manufacturing market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Vaccine Contract Manufacturing market comprises the Middle East, Africa, and Latin America.

North America dominated the Vaccine Contract Manufacturing market due to factors such as advanced healthcare infrastructure, extensive research and development capabilities, and presence of key pharmaceutical companies. Additionally, supportive regulatory environment, robust investments in vaccine development, and strategic collaborations further contributed to North America's substantial market share in this sector, ensuring its position as a global leader in vaccine contract manufacturing.

Europe secured the second largest market share in the Vaccine Contract Manufacturing market due to factors such as a well-established pharmaceutical industry, strong regulatory framework, and access to advanced manufacturing technologies. Additionally, the presence of leading vaccine manufacturers, a skilled workforce, and favorable government initiatives further bolstered Europe's position as a key player in vaccine contract manufacturing on the global stage.

Asia Pacific is experiencing the highest compound annual growth rate (CAGR) in the Vaccine Contract Manufacturing market due to factors such as increasing healthcare expenditure, rising demand for vaccines, and expanding pharmaceutical industry. Moreover, favorable government policies, growing investments in healthcare infrastructure, and the emergence of contract manufacturing organizations further drive market growth in the region.

Furthermore, the rest of the world's Vaccine Contract Manufacturing market is divided into the Middle East, Africa, and Latin America. The rest of the world is witnessing growth in the Vaccine Contract Manufacturing market due to factors such as improving healthcare infrastructure, rising demand for vaccines, and increasing outsourcing by global pharmaceutical companies to leverage cost-effective manufacturing solutions and access specialized expertise in emerging markets outside North America, Europe, and Asia Pacific.

Key Findings of the Study

• The global Vaccine Contract Manufacturing market is expected to reach USD 7.9 billion by 2032, at a CAGR of 11.50% during the forecast period.


• The Asia Pacific region is experiencing the fastest growth in the Vaccine Contract Manufacturing market due to factors such as increasing healthcare expenditure, rising demand for vaccines, and expanding pharmaceutical industry and infrastructure.


• Based on Vaccine Type, the Attenuated segment was attributed to holding the largest market in 2023 with an approximate market share of 35–55%.


• Emergent BioSolutions Inc., Catalent, Inc., Lonza Group AG, Fujifilm Diosynth Biotechnologies, Wuxi Biologics, Samsung Biologics, Boehringer Ingelheim, Novavax, Inc., BioNTech SE, CSL Limited and Others are the key market players.